#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Precision psychiatry – a feasible possibility?


Authors: Eva Češková 1,2,3,4
Authors place of work: CEITEC-MU, Brno 1;  Psychiatrická klinika LF MU a FN Brno 2;  Katedra neurologie a psychiatrie LF UO, Ostrava 3;  Odddělení psychiatrie, FN Ostrava 4
Published in the journal: Čas. Lék. čes. 2019; 158: 328-331
Category: Topic

Summary

Currently, patients are evaluated by a psychiatrist using the phenomenological classification then, first-line treatment is initiated according to the diagnosis; however, this approach is associated with a high rate of etiopathogenetic heterogeneity. The development of mental disorders is likely determined by combined effects of genetic predisposition and environmental adversity. Inter-mutual interaction is regulated by epigenetics processes which determine transcription and translation of gens to corresponding proteins. Choosing the optimal drug among available we strive for individualized approach based upon a patient's clinical characteristics. Personalized medicine including psychiatry considers measurable indicators of pathogenic processes (biomarkers) enabling identification of patients with common biological changes.

Although personalized and precision medicine are often used synonymously, they describe two different approaches. Personalized psychiatry refers to the approach to an individual patient, precision psychiatry empowers decision- making process by measurable indicators and becomes the indispensable vehicle to achieve personalized treatment. An example is schizophrenia, the most severe mental disorder and prototype of psychotic disorder. The current definition of schizophrenia lacks a biological validity, which is stimulating an effort to alternatively define the psychotic disorders on the base of biomarkers. The goal of integration knowledge from biomedical research and clinical practice is providing more accurate diagnosis and the tailored treatment for each individual patient.

Keywords:

Genetics – personalized medicine – precision psychiatry – biomarkers – Schizophrenia – epigenetics.


Zdroje
  1. Wium-Andersen IK, Vinberg M, Kessing LV, McIntyre RS. Personalized medicine in psychiatry. Nord J Psychiatry 2017; 71: 12–19.
  2. Menke A. Precision pharmacotherapy: Psychiatry’s future direction in preventing, diagnosing, and treating mental disorders. Pharmgenomics Pers Med 2018; 11: 211–222.
  3. Fernandes BS, Williams LM, Steiner J et al. The new field of 'precision psychiatry'. BMC Med 2017; 15: 80.
  4. Perna G, Grassi M, Caldirola D, Nemeroff CB. The revolution of personalized psychiatry: will technology make it happen sooner? Psychol Med 2018; 48: 705–713.
  5. Boyle EA, Li YI, Pritchard JK. An expanded view of complex traits: From polygenic to omnigenic. Cell 2017; 169: 1177–1186.
  6. Slabý O, Laga R, Sedláček O. Therapeutic targeting of non-coding RNAs in cancer. Biochem J 2017; 474: 4219–4251.
  7. McVeigh TP, Kerin MJ. Clinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer. Breast Cancer 2017; 9: 393–400.
  8. Nasrallah HA. The dawn of precision psychiatry. Curr Psychiatry 2017; 16: 7–8, 11.
  9. van der Doef TF, Zaragoza Domingo S, Jacobs GE et al. New approaches in psychiatric development. Eur Neuropsychopharmacol 2018; 28: 983–993.
  10. Torrey EF, Yolken RH, Lamb HR. NIMH drug trials for schizophrenia. J Clin Psychiatry 2019; 80(1), pii: 18com12597.
  11. Foley C, Bienvenu OJ. Psychiatric disease versus behavioral diseases and degree of genetic influence. Psychol Med 2011; 41: 33–40.
  12. Reddaway JT, Doherty JL, Lancaster T et al. Genomic and imaging biomarkers in schizophrenia. Curr Top Behav Neurosci 2018; 40: 325–352.
  13. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108- schizophrenia-associated genetic loci. Nature 2014; 511: 421–427.
  14. Giegling I, Hosak L, Mössner R et al. Genetics of schizophrenia: a consensus paper of the WFSBP Task Force on Genetics. World J Biol Psychiatry 2017; 18: 492–505.
  15. Zheutlin AB, Ross DA. Polygenic risk scores: What are they good for? Biol Psychiatry 2018; 83: e51–e53.
  16. Weinberger D. Thinking about schizophrenia in an era of genomic medicine. Am J Psychiatry 2019; 176: 12–20.
  17. Mohammadi A, Rashidi E, Amooeian VG. Brain, blood, cerebrospinal fluid, and serum biomarkers in schizophrenia. Psychiatry Res 2018; 265: 25–38.
  18. Češková E. Význam biologických markerů pro diagnostiku a léčbu schizofrenie. Česká a slovenská psychiatrie 2019; 115: 132–139.
  19. Atkinson AJ, Colburn WA, DeGruttola VG et al.; NIH Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89–95.
  20. Schmitt A, Martins-de-Souza D, Akbarian S et al.; Members of the WFSBP Task Force on Biological Markers. Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia, part III: Molecular mechanisms. World J Biol Psychiatry 2017; 18: 330–356.
  21. Lai CY, Scarr E, Udawela M et al. Biomarkers in schizophrenia: a focus on blood-based diagnostics and theranostics. World J Psychiatry 2016; 6: 102–117.
  22. Ravyn D, Ravyn V, Lowney R, Nasrallah HA. CYP 450 pharmacogenetic treatment strategies for antipsychotics: a review of the evidence. Schizophr Res 2013; 149: 1–14.
Štítky
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management Dental Hygienist

Článok vyšiel v časopise

Journal of Czech Physicians

Najčítanejšie tento týždeň
Najčítanejšie v tomto čísle
Prihlásenie
Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa

#ADS_BOTTOM_SCRIPTS#